eSTAR Now Open For PMA Submissions

The US FDA electronic submission process for streamlining its product review process is now available for sponsors submitting some premarket approval applications.

Electronic Submissions
• Source: Shutterstock

As of 6 December, sponsors may opt to use the Food and Drug Administration’s electronic Submission Template And Resource (eSTAR) template for certain premarket approval applications, including original PMAs, PMA panel track supplements, PMA real-time supplements, and PMA 180-day supplements.

More from Regulation

How Cutting Edge Technology Is Changing Risk Management In the EU

 

Cybersecurity, sustainability and regulatory intelligence all need factoring into risk management today as AI and data availability change the goalposts. Eight experts tell Medtech Insight how compliance efforts must adapt.

EU Commissioner: Medtech Regulations Assessment To Wrap Up by End 2025

 

Pediatric devices and IVDs are to be a priority. And the European Health Data Space regulation is seen as critical in supporting digital technologies and AI in transforming care.

Rapid Action Required For Medtech Compliance With EU Batteries Regulation

 

As deadlines approach, the regulatory landscape for medtech batteries is set to change, with an emphasis on sustainability and ethical practices.

US FDA Should Regulate ‘Dangerous’ Prescription Software Platform As A Medical Device, Says Patient Advocacy Group

The Doctor Patient Forum says the US FDA should regulate a scoring platform from Bamboo Health intended to help clinicians calculate risk for opioid abuse as a medical device to ensure patient safety.

More from Policy & Regulation

Get A Grip On Healthcare And Tariffs German Medtechs Tell Incoming Coalition

 
• By 

The IVD industry’s new 10-point plan for healthcare change shows that medtechs will keep calling the German government to account. Tariffs, sector resilience, digital functionality are among the pressing issues industry wants answers to.

Government Pulls ‘For Sale’ Signs From US FDA’s White Oak Campus

 
• By 

The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.

AI-Based Screening Tool For Musculoskeletal Issues Gets US FDA Warning Letter

 
• By 

Exer Labs Inc.’s website marketed its AI-based Exer Scan app to “screen and treat Parkinson’s, TB, Cerebral Palsy and more.” But those claims went well beyond what was allowed under the product’s 510(k) clearance, US regulators say.